OCREVUS ZUNOVO® (ocrelizumab and hyaluronidase-ocsq): Injection Reactions

PHASE 3 OCARINA II STUDY: INJECTION REACTIONS (WEEK 96[a])[2]

Evaluated in **adult patients with RMS or PPMS** who received at **least one dose of OCREVUS ZUNOVO** in OCARINA II, an active-controlled, open-label, randomized study (N=236)[3]

58% of patients **experienced one or more IRs** (136/233)

In the OCARINA II study, **IRs were more frequently reported with the first injection**

Local injection reactions

55%
had **≥1 local** IRs (129/233)

Most common symptoms
- Erythema: 39%
- Pain: 20%
- Swelling: 12%

Systemic injection reactions

13%
had **≥1 systemic** IRs (31/233)

Most common symptoms
- Headache: 4%
- Flushing: 1%
- Nausea: 1%

REACTION DURATION

Local: median 2 days



Systemic: median 1 day

All IRs were **mild or moderate,** and most **resolved without treatment within 1–3 days**

LOCAL REACTION MEDIAN SIZE



There was a **decrease in reaction size** with subsequent injections[b]

[a]All data from August 7, 2025, clinical cutoff with 96 weeks of follow-up. [b]Where treatment for IRs was administered, the medications were standard of care treatments, including mostly analgesics (eg, ibuprofen or acetaminophen), and oral or topical antihistamines (eg, diphenhydramine or cetirizine).
IR=injection reaction; PPMS=primary progressive multiple sclerosis; RMS=relapsing multiple sclerosis; US=United States.

Genentech
A Member of the Roche Group

PATIENT-REPORTED SIDE EFFECTS: **REAL-WORLD EXPERIENCE**

In **adult patients with RMS or PPMS** who received **OCREVUS ZUNOVO at a single center in the University of Virginia (UVA) Health System** (N=100)[4]

Patient-reported **DISCOMFORT**

IMMEDIATELY
96%
"none to mild"
(4% reported moderate discomfort, and 0% reported severe)

At 72 HOURS
96%
"none to mild"
(2% reported moderate discomfort, and 2% reported severe)

Patient-reported **REDNESS/SWELLING**

IMMEDIATELY
97%
"none to mild"
(3% reported moderate redness/swelling, and 0% reported severe)

At 72 HOURS
92%
"none to mild"
(7% reported moderate redness/swelling, and 1% reported severe)

EXAMPLES OF MILD AND MODERATE **INJECTION REACTIONS**[a]

MILD

MODERATE

[a]*Actual OCREVUS ZUNOVO patients, used with permission. Images are not indicative of the safety profile for OCREVUS ZUNOVO and do not encompass the full injection reaction experience. Systemic reactions are not shown here.*

OCREVUS ZUNOVO:
US PRESCRIBING INFORMATION[1]

Please see full US Prescribing Information for important dosage, administration, and safety information.

PPMS=primary progressive multiple sclerosis; RMS=relapsing multiple sclerosis.

1. Ocrevus Zunovo® (ocrelizumab and hyaluronidase-ocsq) [package insert]. South San Francisco, CA: Genentech USA, Inc.; 2024. https://www.gene.com/download/pdf/ocrevus_zunovo_prescribing.pdf 2. Newsome SD, et al. *Neurology*. 2025;104:e213574. 3. Newsome SD, et al. Presented at: ECTRIMS; September 24–26, 2025; Barcelona, Spain. 4. Holian AH, et al. Presented at: ACTRIMS Forum 2026; February 5–7, 2026; San Diego, CA.

Genentech
A Member of the Roche Group